Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04204434 · ClinicalTrials.gov registry record
Biomarkers For Immune Checkpoint Inhibitors
A clinical trial of Neoplasms and Advanced Cancer, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- 119
- Enrollment target
- 2
- Study locations
NCT04204434 is a study of Neoplasms and Advanced Cancer that has completed, run by Rhode Island Hospital. The registered enrollment target is 119 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04204434, a study of Neoplasms and Advanced Cancer, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Cambridge Massachusetts that will focus on the molecules present in the GI tract, including the stomach, small intestine and colon.
Conditions Studied
Study Locations (2)
Rhode Island
- Rhode Island Hospital - Providence
- The Miriam Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2024-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04204434
The ClinicalTrials.gov registry entry for NCT04204434 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (93% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT04204434 reports 2 study locations spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04204434 about?
NCT04204434 is a clinical study titled "Biomarkers For Immune Checkpoint Inhibitors". This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney can...
What is the current status of trial NCT04204434?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2016-11-29. Estimated completion is 2024-04-26.
What conditions does trial NCT04204434 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Cancer.
Who is sponsoring clinical trial NCT04204434?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04204434 being conducted?
This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.